S100P immunostaining identifies a subset of peripheral-type intrahepatic cholangiocarcinomas with morphological and molecular features similar to those of perihilar and extrahepatic cholangiocarcinomas

Histopathology

Volumn 61, Issue 6, 2012, Pages 1106-1116

  Tsai, Jia Huei ^a   Huang, Wen Chih ^b   Kuo, Kuan Ting ^a   Yuan, Ray Hwang ^c   Chen, Yu Ling ^a   Jeng, Yung Ming ^a,c  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b FAR EASTERN MEMORIAL HOSPITAL   (Taiwan)

^c School of Medicine   (Taiwan)

Author keywords

Immunohistochemistry; Intrahepatic cholangiocarcinoma; K RAS; S100P

Indexed keywords

CA 19-9 ANTIGEN; CALCIUM BINDING PROTEIN; CARCINOEMBRYONIC ANTIGEN; K RAS PROTEIN; MUCIN 2; NERVE CELL ADHESION MOLECULE; S100P PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BILE DUCT; BILE DUCT CANCER; BILE DUCT CARCINOMA; BILIARY TRACT SURGERY; BLOOD SAMPLING; CANCER MORPHOLOGY; CANCER PATIENT; CLINICAL FEATURE; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; EXTRAHEPATIC CHOLANGIOCARCINOMA; FEMALE; GENE FREQUENCY; GENE MUTATION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PERIHILAR CHOLANGIOCARCINOMA; PERIPHERAL INTRAHEPATIC CHOLANGIOCARCINOMA; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SENSITIVITY AND SPECIFICITY; SERUM; TISSUE SECTION; TUMOR DIFFERENTIATION;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, TUMOR-ASSOCIATED, CARBOHYDRATE; BILE DUCT NEOPLASMS; BILE DUCTS, EXTRAHEPATIC; BILE DUCTS, INTRAHEPATIC; CALCIUM-BINDING PROTEINS; CARCINOEMBRYONIC ANTIGEN; CHOLANGIOCARCINOMA; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM PROTEINS; PROGNOSIS; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL;

EID: 84870388626     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2012.04316.x     Document Type: Article

References (28)

1. Bosman FT, Carneiro F, Hruban RH, Theise ND. World Health Organization classification of tumours of the digestive system. Lyon: IARC Press, 2010.
2. Patel T. Worldwide trends in mortality from biliary tract malignancies. BMC Cancer 2002; 2; 10.
3. Okuda K, Nakanuma Y, Miyazaki M. Cholangiocarcinoma: recent progress. Part 1: epidemiology and etiology. J. Gastroenterol. Hepatol. 2002; 17; 1049-1055.
4. Yu TH, Yuan RH, Chen YL, Yang WC, Hsu HC, Jeng YM. Viral hepatitis is associated with intrahepatic cholangiocarcinoma with cholangiolar differentiation and N-cadherin expression. Mod. Pathol. 2011; 24; 810-819.
5. Yamasaki S. Intrahepatic cholangiocarcinoma: macroscopic type and stage classification. J. Hepatobiliary Pancreat. Surg. 2003; 10; 288-291.
6. Bergquist A, Glaumann H, Stal P, Wang GS, Broomé U. Biliary dysplasia, cell proliferation and nuclear DNA-fragmentation in primary sclerosing cholangitis with and without cholangiocarcinoma. J. Intern. Med. 2001; 249; 69-75.
7. Chen TC, Nakanuma Y, Zen Y et al. Intraductal papillary neoplasia of the liver associated with hepatolithiasis. Hepatology 2001; 34; 651-658.
8. Kurathong S, Lerdverasirikul P, Wongpaitoon V, Pramoolsinsap C, Upatham ES. Opisthorchis viverrini infection and cholangiocarcinoma. A prospective, case-controlled study. Gastroenterology 1985; 89; 151-156.
9. Aishima S, Kuroda Y, Nishihara Y et al. Proposal of progression model for intrahepatic cholangiocarcinoma: clinicopathologic differences between hilar type and peripheral type. Am. J. Surg. Pathol. 2007; 31; 1059-1067.
10. 2+ binding properties. Eur. J. Biochem. 1992; 207; 541-547.
11. 2+ signaling S100 proteins and RAGE in translational medicine. Front. Biosci. 2011; 3; 1232-1262.
12. Schaub MC, Heizmann CW. Calcium, troponin, calmodulin, S100 proteins: from myocardial basics to new therapeutic strategies. Biochem. Biophys. Res. Commun. 2008; 369; 247-264.
13. Birkenkamp-Demtroder K, Olesen SH, Sørensen FB et al. Differential gene expression in colon cancer of the caecum versus the sigmoid and rectosigmoid. Gut 2005; 54; 374-384.
14. Diederichs S, Bulk E, Steffen B et al. S100 family members and trypsinogens are predictors of distant metastasis and survival in early-stage non-small cell lung cancer. Cancer Res. 2004; 64; 5564-5569.
15. Hammacher A, Thompson EW, Williams ED. Interleukin-6 is a potent inducer of S100P, which is up-regulated in androgen-refractory and metastatic prostate cancer. Int. J. Biochem. Cell Biol. 2005; 37; 442-450.
16. Wang G, Platt-Higgins A, Carroll J et al. Induction of metastasis by S100P in a rat mammary model and its association with poor survival of breast cancer patients. Cancer Res. 2006; 66; 1199-1207.
17. Arumugam T, Simeone DM, Schmidt AM, Logsdon CD. S100P stimulates cell proliferation and survival via receptor for activated glycation end products (RAGE). J. Biol. Chem. 2004; 279; 5059-5065.
18. 2+-dependent binding and activation of dormant ezrin by dimeric S100P. Mol. Biol. Cell 2003; 14; 2372-2384.
19. Arumugam T, Simeone DM, Van Golen K, Logsdon CD. S100P promotes pancreatic cancer growth, survival, and invasion. Clin. Cancer Res. 2005; 11; 5356-5364.
20. Dowen SE, Crnogorac-Jurcevic T, Gangeswaran R et al. Expression of S100P and its novel binding partner S100PBPR in early pancreatic cancer. Am. J. Pathol. 2005; 166; 81-92.
21. Aishima S, Fujita N, Mano Y et al. Different roles of S100P overexpression in intrahepatic cholangiocarcinoma: carcinogenesis of perihilar type and aggressive behavior of peripheral type. Am. J. Surg. Pathol. 2011; 35; 590-598.
22. Hamada S, Satoh K, Hirota M et al. Calcium-binding protein S100P is a novel diagnostic marker of cholangiocarcinoma. Cancer Sci. 2011; 102; 150-156.
23. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A. AJCC cancer staging manual, 7th edn. New York, NY: Springer, 2010.
24. Zen Y, Aishima S, Ajioka Y et al. Proposal of histological criteria for intraepithelial atypical/proliferative biliary epithelial lesions of the bile duct in hepatolithiasis with respect to cholangiocarcinoma: preliminary report based on interobserver agreement. Pathol. Int. 2005; 55; 180-188.
25. Stroescu C, Herlea V, Dragnea A, Popescu I. The diagnostic value of cytokeratins and carcinoembryonic antigen immunostaining in differentiating hepatocellular carcinomas from intrahepatic cholangiocarcinomas. J. Gastrointestin. Liver Dis. 2006; 15; 9-14.
26. Park SY, Roh SJ, Kim YN et al. Expression of MUC1, MUC2, MUC5AC and MUC6 in cholangiocarcinoma: prognostic impact. Oncol. Rep. 2009; 22; 649-657.
27. Tada M, Yokosuka O, Omata M, Ohto M, Isono K. Analysis of ras gene mutations in human hepatic malignant tumors by polymerase chain reaction and direct sequencing. Cancer Res. 1990; 50; 1121-1124.
28. Tannapfel A, Benicke M, Katalinic A et al. Frequency of p16 (INK4A) alterations and K-ras mutations in intrahepatic cholangiocarcinoma of the liver. Gut 2000; 47; 721-727.